Last updated April 29, 2026
Frequently Asked Questions
- Did VDPHL01 pass clinical trials?
- Phase 2/3 Study ‘302’ reported positive topline results on April 27, 2026. The trial met all primary and key secondary endpoints with high statistical significance. A second pivotal trial (Study ‘304’, 536 men) is fully enrolled with results expected H2 2026. FDA approval requires both studies.
Source: Business Wire, April 27, 2026 - What results were shown in the Phase 2/3 trial?
- In Study ‘302’ (519 men, 6 months):
- Mean hair count increase: +30.3 hairs/cm² (once daily) and +33.0 hairs/cm² (twice daily) vs +7.3 for placebo
- 79–86% of patients reported improvement in hair coverage vs 35.6% placebo
- Statistically significant results observed as early as Month 2
- Investigators independently confirmed improvement in 72–84% of patients
Source: Business Wire, April 27, 2026
- What side effects have been reported?
- In Study ‘302’, the safety profile was favorable:
- No treatment-related serious adverse events (SAEs)
- No cardiac adverse events of special interest (AESIs)
- Overall adverse event rates similar to placebo
- Discontinuation due to adverse events: comparable to placebo
This is a key distinction from standard immediate-release oral minoxidil, which can cause fluid retention, tachycardia, and in rare cases pericardial effusion. VDPHL01’s extended-release formulation is designed to avoid the concentration spikes responsible for those effects.
Source: Veradermics press release, April 27, 2026 - Is VDPHL01 hormone-free?
- Yes. VDPHL01 is an extended-release formulation of minoxidil — a non-hormonal vasodilator. It does not inhibit 5-alpha-reductase or affect DHT levels systemically, unlike finasteride or dutasteride. This makes it potentially suitable for patients who experience or wish to avoid the sexual and mood side effects associated with hormonal treatments.
Source: Veradermics patent WO2025/072131; company disclosures - How does VDPHL01 differ from finasteride?
- Finasteride works by reducing circulating DHT through 5-alpha-reductase inhibition — a hormonal mechanism with documented sexual and psychiatric side effects in a subset of patients. VDPHL01 is oral minoxidil in extended-release form: it promotes hair growth by improving follicular blood supply without touching the hormonal axis. See the comparison table for a full side-by-side.
- How does VDPHL01 differ from off-label low-dose oral minoxidil?
- Both are oral minoxidil, but the formulation is fundamentally different. Standard immediate-release tablets create high concentration peaks in the bloodstream, which is what causes cardiovascular side effects (tachycardia, edema, hypertrichosis). VDPHL01’s proprietary gel-matrix delivers minoxidil gradually — flattening that peak and extending the time the drug stays above the hair-growth threshold. Study ‘302’ is the first large Phase 3 RCT to test oral minoxidil for hair loss at scale with a standardised dose.
- Is VDPHL01 suitable for women?
- A dedicated Phase 2/3 trial in women with female pattern hair loss (Study ‘306’, NCT number: NCT07146022) is actively recruiting. If successful, VDPHL01 would be the first FDA-approved oral treatment for female pattern hair loss. The male studies (302, 304) do not apply directly to women.
Source: Veradermics press release, April 27, 2026; phlstudy.com/female - When will VDPHL01 be available?
- The drug is not approved and not currently available. The projected timeline:
- H2 2026 — Study ‘304’ topline results
- Early 2027 — NDA filing with the FDA (if Study ‘304’ confirms Study ‘302’)
- Late 2027 — Potential approval (priority review scenario)
- Early 2028 — Potential approval (standard review scenario)
These are projections based on Veradermics’ stated plans and standard FDA review timelines. No official approval date has been announced.
- How do I join a clinical trial?
-
- Study ‘302’ and ‘304’ (males): enrollment is complete — these trials are no longer recruiting.
- Study ‘306’ (females): actively recruiting women with pattern hair loss. Visit phlstudy.com/female or NCT07146022 for eligibility criteria and site locations.
- Can VDPHL01 be combined with other hair loss treatments?
- No combination data have been published. As an oral minoxidil formulation, combining VDPHL01 with topical minoxidil would mean using two minoxidil products simultaneously — not studied and not recommended outside a clinical setting. Combination with finasteride or dutasteride has not been formally evaluated in trials.
- Will VDPHL01 be prescription-only?
- Yes. If approved, VDPHL01 will require a physician’s prescription — consistent with how oral minoxidil is currently managed off-label and similar to finasteride.
- What might VDPHL01 cost?
- No pricing has been announced. Analysts project peak U.S. sales of $1.5–2 billion, suggesting a branded launch price likely well above generic finasteride ($25–60/month). Comparable branded specialty dermatology drugs typically launch at $200–400/month before insurance and rebates. Generic competition would depend on Veradermics’ patent exclusivity, which runs to 2043.
- Which countries will launch first?
- Veradermics has indicated simultaneous NDA/MAA filings in the US and EU. Asia-Pacific filings would follow. The US is the primary target market given the approximately 50 million men with pattern hair loss.
This information is for general knowledge only and does not replace professional medical advice. VDPHL01 is an investigational drug and is not approved for use.